[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100548055":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":29,"responsibleParty":45,"collaborators":20,"id":49,"slug":20,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":20,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":20,"enrollmentInfo":57,"targetDuration":20,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":70,"overallStatus":32,"whyStopped":20,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"University of Cincinnati","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Lattice radiation therapy (LRT)","EXPERIMENTAL","Lattice radiation therapy (LRT) : 5 fractions",[13],"Radiation: Lattice therapy (LRT)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Lattice therapy (LRT)","5 Fractions LRT",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"UCCC Clinical Trials Office","CONTACT","513-584-7698","cancer@uchealth.com",{"name":28,"role":24,"phone":20,"phoneExt":20,"email":20},"Andrew Frankart, MD",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"University of Cincinnati Medical Center","RECRUITING","Cincinnati","Ohio","45219","United States",{"type":38,"coordinates":39},"Point",[40,41],-84.51439,39.12711,{"lat":41,"lon":40},[44],{"name":28,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Andrew Frankart","Principal Investigator","100548055",false,"NCT06416007","Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors","A Phase 2 Study of Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors","Inclusion Criteria:\n\n* Solid tumor malignancy with a clinical indication for radiation\n* Patients must have measurable disease\n* Target lesion(s) which are amenable to lattice therapy plan\n* When applicable, target lesion for radiation amenable to immobilization during delivery of radiotherapy\n* Age ≥18 years.\n* ECOG Performance status ≤2\n* Life expectancy greater than 3 months\n* Women of child-bearing potential and men must agree to avoid conception via abstinence (ideal) or a method of birth control (e.g., hormonal or barrier method of birth control) prior to study entry and for at least 30 days after completion of lattice therapy administration.\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Patients receiving cytotoxic chemotherapy or known radiosensitizing agents within 5 days before or after lattice therapy.\n* Patients with hematologic malignancies including lymphoma and leukemia as well as primary or metastatic central nervous system (CNS) malignancies.\n* Patients with a history of conditions which predispose them to increased radiation toxicity\n* Patients with known contraindications to radiation therapy\n* Patients with uncontrolled intercurrent illness\n* Pregnant women","ALL","18 Years",{"count":58,"type":59},37,"ESTIMATED","INTERVENTIONAL",[62],"PHASE2","The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.",[65,66,67,68,69],"Cancer","Metastatic Cancer","Locally Advanced","Locally Advanced Solid Tumor","Locally Advanced Carcinoma",[71,72,73,74,75,76,77],"Radiation","Radiotherapy","Bulky","Spatial fractionation","Lattice therapy","Palliative","Palliation","2026-04-28",{"date":80,"type":81},"2026-05-04","ACTUAL",{"date":83,"type":81},"2024-08-02",{"date":85,"type":59},"2027-06-01",{"name":5,"class":6},1]